Under the leadership of a group of young and promising leading bodies, the company has determined the basic development direction, extensively carried out research and development of new products and cooperated with scientific research institutions and enterprises at home and abroad, and Sihuan Bio is at the forefront of biopharmaceutical field at home and abroad at an unprecedented pace! This product is an anti-tumor biotherapy drug, which is suitable for the treatment of renal cancer, malignant melanoma and cancerous hydrothorax and ascites, and can also be used for the comprehensive treatment of other malignant tumors.
Chinese medicine standard character s 109700 16(50 (110,000 IU/ bottle) Chinese medicine standard character s10970016 (500,000 IU/ bottle)
National medicine standard word s10970017 (200,000 IU/ bottle)
National medicine standard word s 109700 18(65438+ 10,000 IU/ bottle)
National medicine standard word s10970019 (50,000 IU/ bottle)
Interleukin -2(IL-2) is a cytokine secreted by T lymphocytes (a polypeptide consisting of 133 amino acids with a molecular weight of about 15KD). It is the core substance of human immune response, and has the functions of immune enhancement, anti-tumor and anti-infection. Clinically, it has been used to treat renal cancer, melanoma, lymphoma, lung cancer, gastric cancer, breast cancer, ovarian cancer, intestinal cancer, bladder cancer, head and neck tumor, leukemia and cancerous hydrothorax and ascites. Compared with radiotherapy and chemotherapy, interleukin -2 has less toxic and side effects on normal cells, which can alleviate the pain of tumor patients and improve their quality of life. In addition, patients with low immune function such as tuberculosis, hepatitis, AIDS, sexually transmitted diseases and addictive drug users can use interleukin -2. Large doses (6.5438 million units) are used to treat AIDS patients abroad.
"Delesheng" (recombinant human interleukin-2 for injection) is a new national biological product, produced by Beijing Sihuan Biopharmaceutical Co., Ltd., and it is the first genetic engineering product that the scientific research achievements of the national "Eighth Five-Year Plan" and "863" high-tech research and development projects have been transformed into industrial production.
"Development, pilot production and clinical application of genetically engineered human interleukin -2" is a national key scientific and technological project (tackling key problems) and a "863" high-tech research and development project with the project number of 85-722-01-0/. The participating units are the Institute of Bioengineering of the Academy of Military Medical Sciences and the Shanghai Institute of Biochemistry of the Chinese Academy of Sciences, of which the former is responsible for the downstream and pilot tests. Commencement period 1 September 986 1, completion date1September 9961. The project "Development, Pilot Test and Clinical Application of Genetically Engineered Human Interleukin -2" won the "Golden Cup of China Invention Achievement Award" of China Invention Association in 1995, "National Key Scientific and Technological Achievement Award in the Eighth Five-Year Plan" in 1996 and "Gold Award of Beijing International Invention Exhibition" in 1997.
In 199 1, the process of transforming "delosen" into a product was reviewed and approved by the New Drug Evaluation Committee of the Ministry of Health, and recombinant human interleukin-2 was used as a new drug in clinical treatment. 1994 obtained the new drug certificate in June and was approved for trial production in the same year. The approval number is (94) Wei Yao Shenzi (Jinghuan Gong Sheng) S- 0 1-03, and the specifications are 50,000, 65438+100,000 and 200,000. Together with Shanghai Huaxin, it is the first company in China to be approved to trial-produce recombinant human interleukin-2. 1997 was approved for formal production in February, with the production number of (97) Wei Yao Zhunzi (Jinghuan Gong Sheng) S- 0 1-05, with specifications of 50,000, 65,438+10,000, 200,000, 500,000 and 1 10,000 (international units). 1995, 1997, 1998 "Delesheng" products won the honorary title of "Top 100 Recommended Products" in Beijing New Technology Industry Development Experimental Zone. From 1995 to 2000, more than 2 million bottles were produced with an output value of more than 400 million yuan. "Delesheng" is the most influential brand among many domestic interleukin -2 products.
Award-winning situation of Drewson
1994 a new class of national biological products
1995 second prize of military scientific and technological progress
1995 China Jinbei Invention Achievement Award, Top 100 Products in Zhongguancun Science Park, and Drugs Recommended by National biochemical drugs Survey.
1996 national eighth five-year key scientific and technological achievement award, gold medal of Beijing international invention exhibition.
1997 second prize of national scientific and technological progress, awarded by Zhongguancun Science Park 100 fist products.
1998 Zhongguancun science park 100 top commended fist products
1999 The 4th Science and Technology Award
In 2000, Zhongguancun Science Park awarded the fist product-basic medical insurance drug Class B.
New biological products 2
Authentication number:
National Medicine Zhunzi S20020050 (75 μ g/tablet)
National Medicine Zhunzi S2002005 1 (150 μ g/tablet)
National Medicine Zhunzi S20020052 (300 μ g/tablet)
[indications]
1. promotes the increase of neutrophil count after bone marrow transplantation.
2. Neutropenia caused by cancer chemotherapy.
3. Neutropenia associated with myelodysplastic syndrome.
4. Neutropenia associated with aplastic anemia.
5. Congenital and idiopathic neutropenia. National basic medical insurance drugs class B
New biological products 2
Authentication number:
The internal packaging of National Medicine Zhunzi S20020044(2000IU/ piece) is a prefilled syringe.
The internal packaging of the standard word s 2000022(2500 iu/ bottle) of National Medicine is a penicillin bottle.
The internal packaging of National Medicine Zhunzi S20020045(3000IU/ piece) is a prefilled syringe.
The internal packaging of the standard word S20000023(5000IU/ bottle) is a penicillin bottle.